Bank Of New York Mellon Corp Vor Biopharma Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$3.77 - $7.43 $46,163 - $90,980	12,245 New	12,245 $81,000
Q2 2022 Aug 15, 2022	SELL	$3.89 - $6.44 $215,408 - $356,615	-55,375 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$6.04 - $12.23 $9,392 - $19,017	-1,555 Reduced 2.73%	55,375 $335,000
Q4 2021 Feb 11, 2022	BUY	$11.32 - $18.02 $52,966 - $84,315	4,679 Added 8.95%	56,930 $662,000
Q3 2021 Nov 12, 2021	BUY	$12.24 - $20.38 $223,845 - $372,709	18,288 Added 53.85%	52,251 $819,000
Q2 2021 Aug 11, 2021	BUY	$18.65 - $38.78 $71,280 - $148,217	3,822 Added 12.68%	33,963 $633,000
Q1 2021 May 13, 2021	BUY	$30.96 - $54.08 $933,165 - $1.63 Million	30,141 New	30,141 $1.3 Million

41.1M

9.3K

100

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $53.3M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.